Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ranitidine
Drug ID BADD_D01913
Description Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries.[A176843] Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818]
Indications and Usage This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose. In addition to the above, ranitidine can be used for the treatment of GERD symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.[L10818,L10821]
Marketing Status approved; withdrawn
ATC Code Not Available
DrugBank ID DB00863
KEGG ID D00422
MeSH ID D011899
PubChem ID 3001055
TTD Drug ID D0B8WN
NDC Product Code 43353-445; 53746-253; 69842-869; 55111-404; 68462-249; 71713-203; 62207-773; 68196-985; 0121-4727; 50268-721; 63868-482; 65162-254; 69842-871; 71335-1327; 0121-0727; 43598-808; 68462-248; 0904-6921; 53746-254; 62207-774; 71335-1621; 11673-849; 27241-109; 30142-505; 45865-416; 63868-480; 65162-664; 67296-1586; 0904-6715; 64679-740; 65162-253; 70000-0033; 55111-131; 64679-741; 27241-110
UNII 884KT10YB7
Synonyms Ranitidine | Ranitidin | N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine | Biotidin | Ranisen | Sostril | Zantac | Zantic | AH-19065 | AH 19065 | AH19065 | Ranitidine Hydrochloride | Hydrochloride, Ranitidine
Chemical Information
Molecular Formula C13H22N4O3S
CAS Registry Number 82530-72-1
SMILES CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neuroendocrine tumour16.24.01.009; 05.08.01.0130.000055%Not Available
Small intestine carcinoma16.13.13.002; 07.21.01.0160.000975%Not Available
Colon cancer metastatic16.13.01.012; 07.21.01.0100.000038%Not Available
Neuroendocrine carcinoma16.24.01.007; 05.08.01.0110.000038%Not Available
Bladder mass20.03.01.0180.000075%Not Available
Pancreatic carcinoma stage IV16.13.10.005; 07.21.09.0080.000075%Not Available
Malignant peritoneal neoplasm07.21.03.005; 16.13.04.0050.000038%Not Available
Salivary gland cancer16.13.12.001; 07.21.07.0080.000050%Not Available
Gastric cancer stage IV16.13.03.003; 07.21.02.0030.000025%Not Available
Single functional kidney20.01.02.0190.000025%Not Available
Invasive ductal breast carcinoma16.10.01.013; 21.05.01.0210.000075%Not Available
Invasive lobular breast carcinoma21.05.01.022; 16.10.01.0140.000038%Not Available
Lobular breast carcinoma in situ21.05.01.023; 16.10.01.0150.000025%Not Available
Clear cell renal cell carcinoma20.01.04.008; 16.08.02.004--Not Available
Anal squamous cell carcinoma16.13.05.002; 07.21.05.0040.000025%Not Available
Appendix cancer16.13.01.011; 07.21.01.0090.000113%Not Available
Large intestine benign neoplasm16.05.01.004; 07.20.01.0130.000025%Not Available
Anisomastia21.05.04.0130.000025%Not Available
Benign neoplasm of bladder20.03.04.007; 16.27.02.0020.000025%Not Available
Bladder cancer stage II20.03.04.008; 16.08.01.0050.000100%Not Available
Bladder cancer stage III20.03.04.009; 16.08.01.0060.000038%Not Available
Bladder cancer stage IV20.03.04.010; 16.08.01.0070.000075%Not Available
Bladder hypertrophy20.03.01.0250.000025%Not Available
Bladder papilloma20.03.04.011; 16.27.02.0030.000038%Not Available
Bladder wall calcification20.03.01.0260.000025%Not Available
Cardiac neoplasm unspecified16.16.03.004; 02.10.01.0040.000050%Not Available
Colorectal cancer stage I16.13.01.019; 07.21.01.0190.000050%Not Available
Colorectal cancer stage III16.13.01.020; 07.21.01.0200.000250%Not Available
Ductal adenocarcinoma of pancreas16.13.10.006; 07.21.09.0110.000025%Not Available
Duodenal neoplasm16.13.11.006; 07.21.04.0130.000038%Not Available
The 12th Page    First    Pre   12 13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene